Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathias Dahlmann

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Cancers|January 11, 2022
Combination of Wnt/β-Catenin Targets S100A4 and DKK1 Improves Prognosis of Human Colorectal CancerMathias Dahlmann, Anne Monks, Erik D Harris, et al.
Oncogene|July 11, 2021
The newly identified MEK1 tyrosine phosphorylation target MACC1 is druggable by approved MEK1 inhibitors to restrict colorectal cancer metastasisDennis Kobelt, Daniel Perez-Hernandez, Claudia Fleuter, et al.
Cellular and Molecular Life Sciences : CMLS|January 20, 2021
MACC1 regulates clathrin-mediated endocytosis and receptor recycling of transferrin receptor and EGFR in colorectal cancerFrancesca Imbastari, Mathias Dahlmann, Anje Sporbert, et al.
Peptides|November 30, 2023
EPI-X4, a CXCR4 antagonist inhibits tumor growth in pancreatic cancer and lymphoma modelsMicah N Sagini, Michael Zepp, Ergül Eyol, et al.
Cancers|June 16, 2019
Circulating MACC1 Transcripts in Glioblastoma Patients Predict Prognosis and Treatment ResponseCarsten Hagemann, Nikolas Neuhaus, Mathias Dahlmann, et al.
Frontiers in Oncology|April 28, 2023
Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signaturesJoshua Alcaniz, Lars Winkler, Mathias Dahlmann, et al.
Cancers|December 23, 2023
Establishment and Thorough Characterization of Xenograft (PDX) Models Derived from Patients with Pancreatic Cancer for Molecular Analyses and Chemosensitivity TestingDiana Behrens, Ulrike Pfohl, Theresia Conrad, et al.
Plos Biology|June 2, 2017
Statin and rottlerin small-molecule inhibitors restrict colon cancer progression and metastasis via MACC1Manisha Juneja, Dennis Kobelt, Wolfgang Walther, et al.
Frontiers in Oncology|July 8, 2022
A Molecularly Characterized Preclinical Platform of Subcutaneous Renal Cell Carcinoma (RCC) Patient-Derived Xenograft Models to Evaluate Novel Treatment StrategiesDennis Gürgen, Michael Becker, Mathias Dahlmann, et al.
Molecular Cancer|October 21, 2021
Peritoneal metastasis of colorectal cancer (pmCRC): identification of predictive molecular signatures by a novel preclinical platform of matching pmCRC PDX/PD3D modelsMathias Dahlmann, Guido Gambara, Bernadette Brzezicha, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Cancers|January 11, 2022
Combination of Wnt/β-Catenin Targets S100A4 and DKK1 Improves Prognosis of Human Colorectal CancerMathias Dahlmann, Anne Monks, Erik D Harris, et al.
Oncogene|July 11, 2021
The newly identified MEK1 tyrosine phosphorylation target MACC1 is druggable by approved MEK1 inhibitors to restrict colorectal cancer metastasisDennis Kobelt, Daniel Perez-Hernandez, Claudia Fleuter, et al.
Cellular and Molecular Life Sciences : CMLS|January 20, 2021
MACC1 regulates clathrin-mediated endocytosis and receptor recycling of transferrin receptor and EGFR in colorectal cancerFrancesca Imbastari, Mathias Dahlmann, Anje Sporbert, et al.
Peptides|November 30, 2023
EPI-X4, a CXCR4 antagonist inhibits tumor growth in pancreatic cancer and lymphoma modelsMicah N Sagini, Michael Zepp, Ergül Eyol, et al.
Cancers|June 16, 2019
Circulating MACC1 Transcripts in Glioblastoma Patients Predict Prognosis and Treatment ResponseCarsten Hagemann, Nikolas Neuhaus, Mathias Dahlmann, et al.
Frontiers in Oncology|April 28, 2023
Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signaturesJoshua Alcaniz, Lars Winkler, Mathias Dahlmann, et al.
Cancers|December 23, 2023
Establishment and Thorough Characterization of Xenograft (PDX) Models Derived from Patients with Pancreatic Cancer for Molecular Analyses and Chemosensitivity TestingDiana Behrens, Ulrike Pfohl, Theresia Conrad, et al.
Plos Biology|June 2, 2017
Statin and rottlerin small-molecule inhibitors restrict colon cancer progression and metastasis via MACC1Manisha Juneja, Dennis Kobelt, Wolfgang Walther, et al.
Frontiers in Oncology|July 8, 2022
A Molecularly Characterized Preclinical Platform of Subcutaneous Renal Cell Carcinoma (RCC) Patient-Derived Xenograft Models to Evaluate Novel Treatment StrategiesDennis Gürgen, Michael Becker, Mathias Dahlmann, et al.
Molecular Cancer|October 21, 2021
Peritoneal metastasis of colorectal cancer (pmCRC): identification of predictive molecular signatures by a novel preclinical platform of matching pmCRC PDX/PD3D modelsMathias Dahlmann, Guido Gambara, Bernadette Brzezicha, et al.
Pageof 3